Aktis Oncology (NASDAQ:AKTS) Receives Average Rating of "Buy" from Brokerages

Key Points

• Analysts give Aktis Oncology a consensus Buy rating (five analysts) with an average 12-month price target of $32.00.
• Several firms recently initiated or updated coverage—JPMorgan (overweight, $30 target), Bank of America (buy, $34), TD Cowen (buy), and HC Wainwright (raised target to $33)—while Wall Street Zen rated it a hold.
• Shares opened at $20.09 (down ~5.5%), trading below analyst targets, and the company reported a large quarterly loss of ($18.17) EPS on $1.87M revenue with sell-side expectations of roughly -1.39 EPS for the year.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) has been given a consensus recommendation of "Buy" by the five analysts that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $32.00.

Several research firms recently commented on AKTS. JPMorgan Chase & Co. began coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued an "overweight" rating and a $30.00 price objective for the company. Bank of America began coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a "buy" rating and a $34.00 target price on the stock. TD Cowen initiated coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued a "buy" rating for the company. HC Wainwright lifted their price target on Aktis Oncology from $30.00 to $33.00 and gave the company a "buy" rating in a research report on Tuesday, March 31st. Finally, Wall Street Zen upgraded Aktis Oncology to a "hold" rating in a research note on Saturday, January 17th.

Aktis Oncology Stock Down 5.5%

Shares of AKTS opened at $20.09 on Tuesday. The business has a 50-day moving average price of $18.75. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $29.16.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) last issued its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The business had revenue of $1.87 million for the quarter. Sell-side analysts expect that Aktis Oncology will post -1.39 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology NASDAQ: AKTS is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.